# The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/the-efficacy-and-safety-of-combined-immune-checkpoint-inhibitors-nivolumab-plus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jingjie Chen,Shengnan Li,Qigu Yao,Nannan Du,Xiaojun Fu,Yuanmei Lou,Mengru Wang,Feiyan Mao,Danyi Mao,Parikshit Asutosh Khadaroo,Yingying Tang |
| Citations | 47 |
| DOI | 10.1186/s12957-020-01933-5 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://wjso.biomedcentral.com/track/pdf/10.1186/s12957-020-01933-5 |
| OpenAlex ID | https://openalex.org/W3040085298 |
| PMID | 32620130 |
| Type | review |
| Year | 2020 |

## Paper authors

- [Nannan Du](https://scholariq.org/researchers/nannan-du/)

## Paper journal

- [World Journal of Surgical Oncology](https://scholariq.org/journals/world-journal-of-surgical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.